BKBeliz Karataş

Beliz Karataş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beliz Karataş has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Secondary Anti-phospholipid Antibody Syndrome Due to Systemic Lupus Erythematosus: A Case Report with Superior Mesenteric Artery Involvement

    by Ali Sahin, Hatice Şeyma Eren, Gizem Pire, Neşe Çabuk Çelik, Beliz Karataş, İlker Yalçın

    Antiphospholipid antibody syndrome (APS); is a disease characterized by anti-phospholipid protein antibody positivity as well as recurrent vascular thrombosis and/or pregnancy loss. When no underlying disease is detected, it is classified as primary type; when there is another underlying rheumatologic disease, it is classified as secondary type. Secondary APS, most commonly develops due to systemic lupus erythematosus (SLE). We present a case of ischemic colitis due to superior mesenteric artery involvement in APS. 59-year-old female patient diagnosed with SLE had sudden-onset hematochezia and acute abdomen. Therefore, the patient underwent contrast-enhanced computed tomography angiography (CT angiography). Thrombosis was detected in the superior mesenteric artery. This case was interesting in terms of different vascular involvement and treatment strategy in the gastrointestinal tract due to APS.

  • Factors Affecting Survival on Biologic Treatments in Patients with Rheumatoid Arthritis: A Single-Center Study From Turkey

    by Beliz Karataş, Barış YILMAZER

    Objective: In our study, we aimed to determine the factors affecting survival on biologic treatment in adult rheumatoid arthritis (RA) patients using biolog- ical drugs. Materials and Methods: In our study, the data of 245 patients who were followed up with the diagnosis of RA in the Rheumatology Clinic of Trakya University Medical Faculty Hospital between 2013 and 2016 were analyzed retrospectively. 37 patients were excluded due to missing data. The data of the remaining 208 patients were evaluated. Results: In our study, we found that drug survival was reduced by 0.48 times (95% CI 0.23-0.97) in elderly patients and 3 times (95% CI 1.09-10.3) in females. According to the results of our study, drug survival is shortened 8 times (95% CI 2.12-32.5) in patients with hyperlipidemia and 1.03 times (95% CI 1.01-1.04) in patients with high pretreatment erythrocyte sedimentation rate (ESR). In addition, we found that shorter drug survival 9.2 times (95% CI 2.4-35.3) in patients with Hepatitis B surface antigen (HBsAg) positivity, 2.9 times (95% CI 1.3-6.4) in patients with antibody positivity against citrullinated protein (ACPA), in patients using glucocorticoids 0.36 times (95% CI 0.17-0.76). Despite that; in patients with chronic kidney disease, drug survival was prolonged by 0.18 times (95% CI 0.06-0.57). Conclusion: When starting biologic drugs in RA patients, some parameters may help to predict drug survival. According to the order of effect; while HBsAg positivity, presence of hyperlipidemia, female gender, ACPA positivity, high ESR, advanced age and glucocorticoid use were negative markers for drug survival; chronic kidney damage can be a positive marker.

  • Open Access

    Paradoxically Psoriasis, developed in a patient using adalimumab for ankylosing spondylitis: Case report

    by Sena İrki̇n, Neşe ÇABUK ÇELİK, Burak Karakaş, Beliz Karataş, Ali Şahi̇n

    Anti-tumor necrosis factor agents are effective drugs for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Although it is indicated for the treatment of Ankylosing Spondylitis, there are recent publications about paradoxical side effects due to these agents, mostly in the form of case reports. In this article, we present the psoriasis case that develops paradoxically in a patient with ankylosing spondylitis using adalimumab.